NYSE:MCK
MCKESSON CORP
A massive global healthcare distributor generating over $359B in revenue with strong operational cash flow of $6.08B.
Key Metrics
Investment Thesis
Bull Case
Investors may buy McKesson due to its dominant market position offering stable recurring revenue streams and high barriers to entry for competitors. The company's ability to generate substantial free cash flow allows for consistent shareholder returns through dividends and share repurchases, as well as strategic acquisitions. Long-term secular trends in healthcare spending and the need for digital transformation support sustained growth potential.
Bear Case
Bearish investors point to the company's negative shareholders' equity of -$1.69B indicating leverage concerns and potential capital structure fragility. High operating expenses relative to revenue could compress margins if competition intensifies or if regulatory bodies impose stricter price controls on drug distribution. The heavy reliance on volume growth makes the stock sensitive to economic recessions that could force hospitals to cut supply chain budgets.
About MCKESSON CORP
McKesson Corporation operates as a leading healthcare distributor providing pharmaceuticals, medical supplies, and technology solutions to hospitals, pharmacies, and retail chains. The company serves a vast network of customers across the United States through its diverse segments including specialty healthcare, general merchandise, and pharmacy services. Its scale allows it to offer comprehensive supply chain solutions essential for modern healthcare delivery systems.
Analysis
Management Discussion
McKesson reported revenue growth of $50B year-over-year driven by volume expansion in its specialty and general merchandise segments. Operational cash flow surged to $6.08B, reflecting strong working capital management despite a significant increase in accounts payable of $8.30B. The company successfully navigated inflationary pressures while maintaining robust profitability with net income of $3.48B.
Industry Overview
The healthcare distribution industry is characterized by high barriers to entry due to massive capital requirements for logistics networks and established relationships with major pharmaceutical manufacturers. Regulatory scrutiny regarding drug pricing and transparency remains a persistent headwind, while technological adoption drives efficiency gains across the sector. Consolidation trends continue as smaller players struggle to compete with the economies of scale held by giants like McKesson.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | $276.71B | $308.95B | $359.05B |
| Cost of Revenue | $264.35B | $296.12B | $345.73B |
| Gross Profit | $12.36B | $12.83B | $13.32B |
| Operating Expenses | $7.98B | $8.92B | $8.90B |
| Operating Income | $4.38B | $3.91B | $4.42B |
| G&A | $7.78B | $8.66B | $8.51B |
| Stock-Based Comp | $162.0M | $182.0M | $226.0M |
| D&A | $272.0M | $279.0M | $272.0M |
| Depreciation | $248.0M | $253.0M | $242.0M |
| Amortization | $236.0M | $249.0M | $226.0M |
| Other OpEx | $201.0M | $262.0M | $394.0M |
| Non-Operating Income | $249.0M | $-120.0M | $-63.0M |
| Interest Expense | $248.0M | $252.0M | — |
| Interest Income | $107.0M | $118.0M | $173.0M |
| Pre-Tax Income | $4.63B | $3.79B | $4.36B |
| Income Tax | $905.0M | $629.0M | $878.0M |
| Continuing Ops | $3.73B | $3.16B | $3.48B |
| Discontinued Ops | $-3.0M | $0 | $0 |
| Net Income | $3.72B | $3.16B | $3.48B |
| Minority Interest | $162.0M | $158.0M | $186.0M |
| Net to Common | $3.56B | $3.00B | $3.29B |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Current Assets | $44.29B | $47.97B | $55.40B |
| Cash & Equivalents | $4.68B | $4.58B | $5.69B |
| Inventory | $19.69B | $21.14B | $23.00B |
| Prepaid Expenses | $496.0M | $626.0M | $1.06B |
| Other Current Assets | $19.43B | $21.62B | $25.64B |
| Long-Term Assets | $18.03B | $19.47B | $19.74B |
| PP&E (Net) | $2.18B | $2.32B | $2.50B |
| Goodwill | $9.95B | $10.13B | $10.02B |
| Operating Leases | $1.64B | $1.73B | $1.78B |
| Other LT Assets | $4.27B | $5.30B | $5.44B |
| Total Assets | $62.32B | $67.44B | $75.14B |
| Current Liabilities | $47.96B | $52.36B | $61.60B |
| Accounts Payable | $42.49B | $47.10B | $55.33B |
| Current Leases | $299.0M | $295.0M | $258.0M |
| Other Current Liab | $973.0M | $50.0M | $1.19B |
| Long-Term Liabilities | $15.85B | $16.68B | $15.23B |
| LT Operating Leases | $1.40B | $1.47B | $1.48B |
| Other LT Liab | $14.45B | $15.22B | $13.75B |
| Total Liabilities | $63.81B | $69.04B | $76.83B |
| Shareholders' Equity | $-1.49B | $-1.60B | $-1.69B |
| Paid-In Capital | $7.75B | $8.05B | $8.37B |
| Retained Earnings | $12.29B | $14.98B | $17.92B |
| AOCI | $-905.0M | $-881.0M | $-932.0M |
| Total L&E | $62.32B | $67.44B | $75.14B |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Net Income (CFO) | $3.72B | $3.16B | $3.48B |
| Non-Cash Adjustments | $-4.68B | $-8.24B | $-11.75B |
| Working Capital Changes | $6.12B | $9.39B | $14.36B |
| Cash from Operations | $5.16B | $4.31B | $6.08B |
| Capital Expenditures | $390.0M | $431.0M | $537.0M |
| Cash from Investing | $-542.0M | $-1.07B | $-733.0M |
| Debt Issuances | $997.0M | $991.0M | $498.0M |
| Debt Repayments | $1.27B | $288.0M | $519.0M |
| Share Buybacks | $3.64B | $3.02B | $3.15B |
| Dividends Paid | $292.0M | $314.0M | $345.0M |
| Cash from Financing | $-4.37B | $-3.34B | $-3.96B |
| FX Effect | $25.0M | $6.0M | $-16.0M |
| Net Change in Cash | $744.0M | $-94.0M | $1.37B |
| Beginning Cash | $3.94B | $4.68B | $4.58B |
| Ending Cash | $4.68B | $4.58B | $5.96B |
Frequently Asked Questions
How does MCKESSON CORP make money?
Specialty Healthcare (high-margin oncology and gene therapy distribution), General Merchandise (surgical supplies and equipment), and Pharmacy Services (pharmacy benefit management for insurers and retail pharmacies).
What are the main risks for MCK?
Regulatory pressure on pharmaceutical pricing and reimbursement rates, potential erosion of margins from rising operating expenses and logistics costs, sensitivity to macroeconomic downturns affecting discretionary medical spending, and cybersecurity threats within complex health data networks.
What is MCK's competitive advantage?
Unmatched scale providing deep network access to nearly every hospital and pharmacy in the US, significant economies of scope across diverse product lines, and proprietary technology platforms that streamline healthcare supply chains.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.